<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:d614c307-4118-4611-a8d3-3c89a1b9f878,g:1f7774dc-f1ff-4a69-952a-c8825acf6b9a-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CoverPage" xlink:type="simple" xlink:href="vnda-20201231.xsd#CoverPage"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/CoverPage" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="vnda-20201231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_05326254-63cb-4ce2-b170-7a42d1559f4e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_4a589940-1f90-4452-997d-178606da939d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_05326254-63cb-4ce2-b170-7a42d1559f4e" xlink:to="loc_us-gaap_LiabilitiesCurrent_4a589940-1f90-4452-997d-178606da939d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_d2b6daa6-84ae-4673-a4ce-2fedbb42c04c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_05326254-63cb-4ce2-b170-7a42d1559f4e" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_d2b6daa6-84ae-4673-a4ce-2fedbb42c04c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c31437fb-1e08-4fb6-bf02-dc0f325057b2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_05326254-63cb-4ce2-b170-7a42d1559f4e" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c31437fb-1e08-4fb6-bf02-dc0f325057b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_c8c995b2-815b-4dd0-9965-e2383b95b4f3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_54012679-7dc3-48f1-b2a9-47c2ed1a9c7a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c8c995b2-815b-4dd0-9965-e2383b95b4f3" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_54012679-7dc3-48f1-b2a9-47c2ed1a9c7a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_4ded1184-ea1e-4b91-a96f-cb74eb81c2f4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c8c995b2-815b-4dd0-9965-e2383b95b4f3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_4ded1184-ea1e-4b91-a96f-cb74eb81c2f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_a667eee4-7c49-4f05-a9c1-85859115a384" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c8c995b2-815b-4dd0-9965-e2383b95b4f3" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_a667eee4-7c49-4f05-a9c1-85859115a384" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_4cf77884-0e7f-4a3a-b187-6aa95776773e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c8c995b2-815b-4dd0-9965-e2383b95b4f3" xlink:to="loc_us-gaap_InventoryNet_4cf77884-0e7f-4a3a-b187-6aa95776773e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ffc47c8c-f003-49fc-b79e-3a5f85b2d5de" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c8c995b2-815b-4dd0-9965-e2383b95b4f3" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ffc47c8c-f003-49fc-b79e-3a5f85b2d5de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_3f8ea3b7-7193-451c-8366-af6c1e375b9a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_eb09d83a-01e6-4e11-a500-ddfe476ec033" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_3f8ea3b7-7193-451c-8366-af6c1e375b9a" xlink:to="loc_us-gaap_Liabilities_eb09d83a-01e6-4e11-a500-ddfe476ec033" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_15ff443c-0a7b-49b6-9008-775b877ffc97" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_3f8ea3b7-7193-451c-8366-af6c1e375b9a" xlink:to="loc_us-gaap_StockholdersEquity_15ff443c-0a7b-49b6-9008-775b877ffc97" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_454d8926-c7c1-475c-a55a-2579105ce829" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_3f8ea3b7-7193-451c-8366-af6c1e375b9a" xlink:to="loc_us-gaap_CommitmentsAndContingencies_454d8926-c7c1-475c-a55a-2579105ce829" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_5d90e347-b5af-4910-bd43-6d46986387b9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_f3807eb6-89a1-4463-a76d-552919f52c18" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_5d90e347-b5af-4910-bd43-6d46986387b9" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_f3807eb6-89a1-4463-a76d-552919f52c18" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_ProductRevenueAllowancesCurrent_533a84a9-0be3-4ee2-b236-34c8c6294495" xlink:href="vnda-20201231.xsd#vnda_ProductRevenueAllowancesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_5d90e347-b5af-4910-bd43-6d46986387b9" xlink:to="loc_vnda_ProductRevenueAllowancesCurrent_533a84a9-0be3-4ee2-b236-34c8c6294495" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_3b26d095-c699-4b4f-b83c-40eaf34713f9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_e2a0e044-9a3f-4344-b2fd-0ca796405fd0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_3b26d095-c699-4b4f-b83c-40eaf34713f9" xlink:to="loc_us-gaap_PreferredStockValue_e2a0e044-9a3f-4344-b2fd-0ca796405fd0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_269b1120-3100-42bc-9ba6-73fcc687dc3c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_3b26d095-c699-4b4f-b83c-40eaf34713f9" xlink:to="loc_us-gaap_CommonStockValue_269b1120-3100-42bc-9ba6-73fcc687dc3c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_89673a84-dcda-44ac-bc0a-a6160eb7c16e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_3b26d095-c699-4b4f-b83c-40eaf34713f9" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_89673a84-dcda-44ac-bc0a-a6160eb7c16e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_279c5721-f6cf-4086-a2d4-2349526742e2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_3b26d095-c699-4b4f-b83c-40eaf34713f9" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_279c5721-f6cf-4086-a2d4-2349526742e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_9310e743-41b4-4da8-9d80-1cad5cf85771" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_3b26d095-c699-4b4f-b83c-40eaf34713f9" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_9310e743-41b4-4da8-9d80-1cad5cf85771" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_fd0ce91c-c695-488f-8247-4354228c7060" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_72187e0b-c247-4898-881b-cd6e81b0509b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_fd0ce91c-c695-488f-8247-4354228c7060" xlink:to="loc_us-gaap_AssetsCurrent_72187e0b-c247-4898-881b-cd6e81b0509b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_b0125507-805b-4a5b-a5cf-c2672b486095" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_fd0ce91c-c695-488f-8247-4354228c7060" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_b0125507-805b-4a5b-a5cf-c2672b486095" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c2febd7c-6646-4c07-afeb-f3dacde71f6f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_fd0ce91c-c695-488f-8247-4354228c7060" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c2febd7c-6646-4c07-afeb-f3dacde71f6f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_InventoryAndOtherNonCurrent_03fe08d7-aef6-4282-a378-fefa651b504f" xlink:href="vnda-20201231.xsd#vnda_InventoryAndOtherNonCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_fd0ce91c-c695-488f-8247-4354228c7060" xlink:to="loc_vnda_InventoryAndOtherNonCurrent_03fe08d7-aef6-4282-a378-fefa651b504f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_f99435ed-2b35-4565-94d3-2ade2a0b1310" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_fd0ce91c-c695-488f-8247-4354228c7060" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_f99435ed-2b35-4565-94d3-2ade2a0b1310" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_b1c354bd-eb83-49ab-b2c7-bd84d5303d44" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_fd0ce91c-c695-488f-8247-4354228c7060" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_b1c354bd-eb83-49ab-b2c7-bd84d5303d44" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="vnda-20201231.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="vnda-20201231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1640d5a8-f544-4d88-bcbc-5ba81910a309" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_af93e3cf-46c2-4890-afa4-ce5d6b205841" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1640d5a8-f544-4d88-bcbc-5ba81910a309" xlink:to="loc_us-gaap_OperatingIncomeLoss_af93e3cf-46c2-4890-afa4-ce5d6b205841" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncome_8dfb20c4-27dc-43f7-a21d-d77b26989b77" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherIncome"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1640d5a8-f544-4d88-bcbc-5ba81910a309" xlink:to="loc_us-gaap_OtherIncome_8dfb20c4-27dc-43f7-a21d-d77b26989b77" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_8c86b734-3a34-4ebd-9102-5f21931cf191" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0cae88d1-711a-4073-92e0-1a689278af5b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_8c86b734-3a34-4ebd-9102-5f21931cf191" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0cae88d1-711a-4073-92e0-1a689278af5b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_4ffda812-402a-4eab-92e1-2d647c4c9745" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_1d93f9fe-3e1d-4b9b-8100-02d3025aa05a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_4ffda812-402a-4eab-92e1-2d647c4c9745" xlink:to="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_1d93f9fe-3e1d-4b9b-8100-02d3025aa05a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_b243259f-63cc-48da-a0bb-5787fbde468e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_4ffda812-402a-4eab-92e1-2d647c4c9745" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_b243259f-63cc-48da-a0bb-5787fbde468e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_ef1bb7af-16cd-4d19-8848-8755c5cd94da" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_4ffda812-402a-4eab-92e1-2d647c4c9745" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_ef1bb7af-16cd-4d19-8848-8755c5cd94da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_ebf9e8c1-cdd2-474b-9eab-30dbbbfc6a24" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_4ffda812-402a-4eab-92e1-2d647c4c9745" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_ebf9e8c1-cdd2-474b-9eab-30dbbbfc6a24" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_a98d86a1-d937-472f-90ea-c9544c4c02bf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_449e1f37-9523-4e01-b918-40134a92f225" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_a98d86a1-d937-472f-90ea-c9544c4c02bf" xlink:to="loc_us-gaap_Revenues_449e1f37-9523-4e01-b918-40134a92f225" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_afb8334b-1078-4961-afec-4579dda96467" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_a98d86a1-d937-472f-90ea-c9544c4c02bf" xlink:to="loc_us-gaap_CostsAndExpenses_afb8334b-1078-4961-afec-4579dda96467" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c7d53d68-6000-4476-8ac3-a7a654531244" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_d999c57a-faad-495e-9bbe-669cbdedf91f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_c7d53d68-6000-4476-8ac3-a7a654531244" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_d999c57a-faad-495e-9bbe-669cbdedf91f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_04d8084a-d352-464d-9262-5b188a8e0cf4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_c7d53d68-6000-4476-8ac3-a7a654531244" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_04d8084a-d352-464d-9262-5b188a8e0cf4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" xlink:type="simple" xlink:href="vnda-20201231.xsd#CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_17fae01f-59fe-4127-84f9-6297ae0c32b1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_b9b72068-52d9-414a-9cf0-f46f2722fb3e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_17fae01f-59fe-4127-84f9-6297ae0c32b1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_b9b72068-52d9-414a-9cf0-f46f2722fb3e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_92d0f98b-53b9-4d80-8789-a58b8b1e1810" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_17fae01f-59fe-4127-84f9-6297ae0c32b1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_92d0f98b-53b9-4d80-8789-a58b8b1e1810" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax_3f892dbd-c891-441a-bcaa-534b9203c82b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_17fae01f-59fe-4127-84f9-6297ae0c32b1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTax_3f892dbd-c891-441a-bcaa-534b9203c82b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_8ad5dcf7-bc12-4936-9586-46a2a6e91ee1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3d417c7b-83a2-4a70-899c-33b3ce5bb388" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_8ad5dcf7-bc12-4936-9586-46a2a6e91ee1" xlink:to="loc_us-gaap_NetIncomeLoss_3d417c7b-83a2-4a70-899c-33b3ce5bb388" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_973a7097-6901-481d-93bf-f11e1a2bc2f3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_8ad5dcf7-bc12-4936-9586-46a2a6e91ee1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_973a7097-6901-481d-93bf-f11e1a2bc2f3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="vnda-20201231.xsd#CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="vnda-20201231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ff31ea33-7d6f-4792-94e4-9a96897ff439" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_2289278e-0d78-4556-95a4-df07d8d8439d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ff31ea33-7d6f-4792-94e4-9a96897ff439" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_2289278e-0d78-4556-95a4-df07d8d8439d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_3f22405f-2cab-4f33-8674-2995acc9cd00" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ff31ea33-7d6f-4792-94e4-9a96897ff439" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_3f22405f-2cab-4f33-8674-2995acc9cd00" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f7b1a7f5-cf31-4914-9f29-82238b6429aa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_227bf70d-545e-457c-83c0-bd0d08cea012" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f7b1a7f5-cf31-4914-9f29-82238b6429aa" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_227bf70d-545e-457c-83c0-bd0d08cea012" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d83f6831-efe9-4199-9688-a8780631b0fa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f7b1a7f5-cf31-4914-9f29-82238b6429aa" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d83f6831-efe9-4199-9688-a8780631b0fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_b89f1215-ad0c-4f7b-a60f-1e005fe87397" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f7b1a7f5-cf31-4914-9f29-82238b6429aa" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_b89f1215-ad0c-4f7b-a60f-1e005fe87397" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_8a35ac99-caa6-41f2-a7bb-dbf79128f8fd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f7b1a7f5-cf31-4914-9f29-82238b6429aa" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_8a35ac99-caa6-41f2-a7bb-dbf79128f8fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f1ebfb70-b436-4e08-9187-550002e4d21c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fa00c59b-c7a1-4512-9872-7a9356e00b3e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f1ebfb70-b436-4e08-9187-550002e4d21c" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fa00c59b-c7a1-4512-9872-7a9356e00b3e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_60ba9ef4-b14d-4abb-a9df-6c78b7a3d17b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f1ebfb70-b436-4e08-9187-550002e4d21c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_60ba9ef4-b14d-4abb-a9df-6c78b7a3d17b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9c99043c-9d83-4015-91e3-eaa53d3d606d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f1ebfb70-b436-4e08-9187-550002e4d21c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9c99043c-9d83-4015-91e3-eaa53d3d606d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b8c2e30c-7fef-48fb-bf81-1a6aea4236ef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f1ebfb70-b436-4e08-9187-550002e4d21c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b8c2e30c-7fef-48fb-bf81-1a6aea4236ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_408d3ca7-6b8a-442f-a7de-1b8c881c3973" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c7dc0d51-d896-42eb-8294-c2c3af9dfe9f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_408d3ca7-6b8a-442f-a7de-1b8c881c3973" xlink:to="loc_us-gaap_NetIncomeLoss_c7dc0d51-d896-42eb-8294-c2c3af9dfe9f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_0b6e6f19-18de-42e8-9917-092484d5c95b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_408d3ca7-6b8a-442f-a7de-1b8c881c3973" xlink:to="loc_us-gaap_Depreciation_0b6e6f19-18de-42e8-9917-092484d5c95b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_9ed8a2d6-9c8b-4fee-9ba7-2bf4b88010fc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_408d3ca7-6b8a-442f-a7de-1b8c881c3973" xlink:to="loc_us-gaap_ShareBasedCompensation_9ed8a2d6-9c8b-4fee-9ba7-2bf4b88010fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_854e01ec-e237-416b-a854-323c246bf8d6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_408d3ca7-6b8a-442f-a7de-1b8c881c3973" xlink:to="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_854e01ec-e237-416b-a854-323c246bf8d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_e05fd818-b532-4693-8c7a-0d564b9aca62" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_408d3ca7-6b8a-442f-a7de-1b8c881c3973" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_e05fd818-b532-4693-8c7a-0d564b9aca62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_50fce6cf-5c21-4ccb-844e-5692013757d9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_408d3ca7-6b8a-442f-a7de-1b8c881c3973" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_50fce6cf-5c21-4ccb-844e-5692013757d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_05573bc7-206f-4e55-b617-c38c6d9a6939" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_408d3ca7-6b8a-442f-a7de-1b8c881c3973" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_05573bc7-206f-4e55-b617-c38c6d9a6939" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_6fc72b2d-dc8d-4669-a08f-072221066e9c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_408d3ca7-6b8a-442f-a7de-1b8c881c3973" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_6fc72b2d-dc8d-4669-a08f-072221066e9c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_52166816-28df-499e-b3bf-c02a2078e8a3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_408d3ca7-6b8a-442f-a7de-1b8c881c3973" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_52166816-28df-499e-b3bf-c02a2078e8a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_9ac110ad-714d-43f1-8a4f-50d4e5820e6c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_408d3ca7-6b8a-442f-a7de-1b8c881c3973" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_9ac110ad-714d-43f1-8a4f-50d4e5820e6c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_bbb42608-d05b-43d3-b4cb-fcbee415077e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_408d3ca7-6b8a-442f-a7de-1b8c881c3973" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_bbb42608-d05b-43d3-b4cb-fcbee415077e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_IncreaseDecreaseProductRevenueAllowances_9917b398-e6f0-492f-8e19-ec10b5120db6" xlink:href="vnda-20201231.xsd#vnda_IncreaseDecreaseProductRevenueAllowances"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_408d3ca7-6b8a-442f-a7de-1b8c881c3973" xlink:to="loc_vnda_IncreaseDecreaseProductRevenueAllowances_9917b398-e6f0-492f-8e19-ec10b5120db6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_eacec850-2a7c-4e0a-a94b-7f184f5e1aca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_408d3ca7-6b8a-442f-a7de-1b8c881c3973" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_eacec850-2a7c-4e0a-a94b-7f184f5e1aca" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/BusinessOrganizationandPresentation" xlink:type="simple" xlink:href="vnda-20201231.xsd#BusinessOrganizationandPresentation"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/BusinessOrganizationandPresentation" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/BusinessOrganizationandPresentationDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#BusinessOrganizationandPresentationDetail"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/BusinessOrganizationandPresentationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="vnda-20201231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="vnda-20201231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="vnda-20201231.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesReconciliationCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="vnda-20201231.xsd#SummaryofSignificantAccountingPoliciesReconciliationCashCashEquivalentsandRestrictedCashDetails"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesReconciliationCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ce757eff-ea87-4930-915c-37ae50de7178" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9b1901a8-7838-488b-b0ba-1d3cbe0fef3e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ce757eff-ea87-4930-915c-37ae50de7178" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9b1901a8-7838-488b-b0ba-1d3cbe0fef3e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_2673ed33-dc60-4ede-9fae-cf62f56b33d8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ce757eff-ea87-4930-915c-37ae50de7178" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_2673ed33-dc60-4ede-9fae-cf62f56b33d8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesNetSalesbyProductDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#SummaryofSignificantAccountingPoliciesNetSalesbyProductDetail"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesNetSalesbyProductDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesScheduleofMajorCustomersthatRepresentedMoreThan10ofTotalRevenuesDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#SummaryofSignificantAccountingPoliciesScheduleofMajorCustomersthatRepresentedMoreThan10ofTotalRevenuesDetail"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesScheduleofMajorCustomersthatRepresentedMoreThan10ofTotalRevenuesDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesScheduleofMajorCustomersthatRepresentedMoreThan10ofAccountsReceivableNetDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#SummaryofSignificantAccountingPoliciesScheduleofMajorCustomersthatRepresentedMoreThan10ofAccountsReceivableNetDetail"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesScheduleofMajorCustomersthatRepresentedMoreThan10ofAccountsReceivableNetDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesSummaryofProductReturnAllowanceDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#SummaryofSignificantAccountingPoliciesSummaryofProductReturnAllowanceDetail"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesSummaryofProductReturnAllowanceDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/MarketableSecurities" xlink:type="simple" xlink:href="vnda-20201231.xsd#MarketableSecurities"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/MarketableSecurities" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/MarketableSecuritiesTables" xlink:type="simple" xlink:href="vnda-20201231.xsd#MarketableSecuritiesTables"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/MarketableSecuritiesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/MarketableSecuritiesAvailableForSaleMarketableSecuritiesDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#MarketableSecuritiesAvailableForSaleMarketableSecuritiesDetail"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/MarketableSecuritiesAvailableForSaleMarketableSecuritiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_236e9e9e-d906-45ca-b254-bfa98b428f8f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c09493d8-d933-4671-bdea-47a75ade17ad" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_236e9e9e-d906-45ca-b254-bfa98b428f8f" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c09493d8-d933-4671-bdea-47a75ade17ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_c8bad984-eb55-4282-a1b2-d3c4f78eeea3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_236e9e9e-d906-45ca-b254-bfa98b428f8f" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_c8bad984-eb55-4282-a1b2-d3c4f78eeea3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9b339dad-950b-407b-b0d1-6ff3a3f2bd8b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_236e9e9e-d906-45ca-b254-bfa98b428f8f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9b339dad-950b-407b-b0d1-6ff3a3f2bd8b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="vnda-20201231.xsd#FairValueMeasurements"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/FairValueMeasurements" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="vnda-20201231.xsd#FairValueMeasurementsTables"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/FairValueMeasurementsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetail"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/Inventory" xlink:type="simple" xlink:href="vnda-20201231.xsd#Inventory"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/Inventory" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/InventoryTables" xlink:type="simple" xlink:href="vnda-20201231.xsd#InventoryTables"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/InventoryTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/InventoryDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#InventoryDetail"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/InventoryDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_b8e8f5b6-9af0-461e-92fd-008457f26292" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_InventoryRawMaterialsNetOfReservesNonCurrent_74380255-cc1c-4f5d-a970-8fef398e7c9c" xlink:href="vnda-20201231.xsd#vnda_InventoryRawMaterialsNetOfReservesNonCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNoncurrent_b8e8f5b6-9af0-461e-92fd-008457f26292" xlink:to="loc_vnda_InventoryRawMaterialsNetOfReservesNonCurrent_74380255-cc1c-4f5d-a970-8fef398e7c9c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_InventoryWorkInProcessNetOfReservesNonCurrent_2dc7bbb4-f957-4217-ab69-10b9d677ea40" xlink:href="vnda-20201231.xsd#vnda_InventoryWorkInProcessNetOfReservesNonCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNoncurrent_b8e8f5b6-9af0-461e-92fd-008457f26292" xlink:to="loc_vnda_InventoryWorkInProcessNetOfReservesNonCurrent_2dc7bbb4-f957-4217-ab69-10b9d677ea40" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_InventoryFinishedGoodsNetOfReservesNonCurrent_c4bd037c-e1ba-4a6b-98f8-772ce3ad370d" xlink:href="vnda-20201231.xsd#vnda_InventoryFinishedGoodsNetOfReservesNonCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNoncurrent_b8e8f5b6-9af0-461e-92fd-008457f26292" xlink:to="loc_vnda_InventoryFinishedGoodsNetOfReservesNonCurrent_c4bd037c-e1ba-4a6b-98f8-772ce3ad370d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_Inventory_f4c717dc-ac2b-4e36-a54b-54ca2071aa31" xlink:href="vnda-20201231.xsd#vnda_Inventory"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_f7d5397e-0967-4a51-9eed-52d60d15a2f9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_vnda_Inventory_f4c717dc-ac2b-4e36-a54b-54ca2071aa31" xlink:to="loc_us-gaap_InventoryNoncurrent_f7d5397e-0967-4a51-9eed-52d60d15a2f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_bd15fd7a-bc34-47c5-a604-962dd07af292" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_vnda_Inventory_f4c717dc-ac2b-4e36-a54b-54ca2071aa31" xlink:to="loc_us-gaap_InventoryNet_bd15fd7a-bc34-47c5-a604-962dd07af292" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_e0f1205f-519b-4d50-9400-68a5258a5b07" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_b0b1e663-fd86-4766-8237-fa81ba3753a8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_e0f1205f-519b-4d50-9400-68a5258a5b07" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_b0b1e663-fd86-4766-8237-fa81ba3753a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_12bc63db-2019-422c-abe1-e932e1df6f9e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_e0f1205f-519b-4d50-9400-68a5258a5b07" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_12bc63db-2019-422c-abe1-e932e1df6f9e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/PropertyandEquipment" xlink:type="simple" xlink:href="vnda-20201231.xsd#PropertyandEquipment"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/PropertyandEquipment" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/PropertyandEquipmentTables" xlink:type="simple" xlink:href="vnda-20201231.xsd#PropertyandEquipmentTables"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/PropertyandEquipmentTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/PropertyandEquipmentPropertyandEquipmentatCostDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#PropertyandEquipmentPropertyandEquipmentatCostDetail"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/PropertyandEquipmentPropertyandEquipmentatCostDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1c220cfc-3c59-4a2b-8fc0-337650b77a09" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_658aed92-b1fb-43bb-8d9c-6f061a2a696f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_1c220cfc-3c59-4a2b-8fc0-337650b77a09" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_658aed92-b1fb-43bb-8d9c-6f061a2a696f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1e0c0964-b7c5-4afc-a715-ebf637975e11" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_1c220cfc-3c59-4a2b-8fc0-337650b77a09" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1e0c0964-b7c5-4afc-a715-ebf637975e11" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/PropertyandEquipmentAdditionalInformationDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#PropertyandEquipmentAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/PropertyandEquipmentAdditionalInformationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/Leases" xlink:type="simple" xlink:href="vnda-20201231.xsd#Leases"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/Leases" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/LeasesTables" xlink:type="simple" xlink:href="vnda-20201231.xsd#LeasesTables"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/LeasesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/LeasesAdditionalInformationDetails" xlink:type="simple" xlink:href="vnda-20201231.xsd#LeasesAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/LeasesAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/LeasesLeaseAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="vnda-20201231.xsd#LeasesLeaseAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/LeasesLeaseAssetsandLiabilitiesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/LeasesMaturitiesDetails" xlink:type="simple" xlink:href="vnda-20201231.xsd#LeasesMaturitiesDetails"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/LeasesMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_0d7cc72d-1f75-4a87-86df-bdf88b16d55c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_8d68ddbe-7e60-477d-8d05-209bfb62a30e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_0d7cc72d-1f75-4a87-86df-bdf88b16d55c" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_8d68ddbe-7e60-477d-8d05-209bfb62a30e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_adca047f-00e3-4dfc-b228-ba8f01dac334" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_0d7cc72d-1f75-4a87-86df-bdf88b16d55c" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_adca047f-00e3-4dfc-b228-ba8f01dac334" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5e668ea7-5d0d-4f05-a949-34881721911d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_68286df1-5de2-4484-b640-52980ebd6116" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5e668ea7-5d0d-4f05-a949-34881721911d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_68286df1-5de2-4484-b640-52980ebd6116" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_1df85ce2-3d7c-4be1-a26e-13437f7f29d8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5e668ea7-5d0d-4f05-a949-34881721911d" xlink:to="loc_us-gaap_OperatingLeaseLiability_1df85ce2-3d7c-4be1-a26e-13437f7f29d8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/LeasesMaturitiesDetails_1" xlink:type="simple" xlink:href="vnda-20201231.xsd#LeasesMaturitiesDetails_1"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/LeasesMaturitiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3576e7da-0fd0-4c7b-be3e-271a6bec8ab5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_649aa8e4-285a-4758-8a3c-c2c9182f3b9b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3576e7da-0fd0-4c7b-be3e-271a6bec8ab5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_649aa8e4-285a-4758-8a3c-c2c9182f3b9b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_5e182a04-1541-434f-b14d-b75ce3073372" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3576e7da-0fd0-4c7b-be3e-271a6bec8ab5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_5e182a04-1541-434f-b14d-b75ce3073372" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_9027849d-50d4-4bd3-898e-78159d85b7ca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3576e7da-0fd0-4c7b-be3e-271a6bec8ab5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_9027849d-50d4-4bd3-898e-78159d85b7ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_7a906a46-e7cb-46c7-879c-5beace8e8f6d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3576e7da-0fd0-4c7b-be3e-271a6bec8ab5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_7a906a46-e7cb-46c7-879c-5beace8e8f6d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_06bf68f7-e19c-4d38-bbc7-d6290af37ef5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3576e7da-0fd0-4c7b-be3e-271a6bec8ab5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_06bf68f7-e19c-4d38-bbc7-d6290af37ef5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_a7be60af-9863-4dbf-af8a-dd8b79225dcc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3576e7da-0fd0-4c7b-be3e-271a6bec8ab5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_a7be60af-9863-4dbf-af8a-dd8b79225dcc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/IntangibleAssets" xlink:type="simple" xlink:href="vnda-20201231.xsd#IntangibleAssets"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/IntangibleAssets" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/IntangibleAssetsTables" xlink:type="simple" xlink:href="vnda-20201231.xsd#IntangibleAssetsTables"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/IntangibleAssetsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/IntangibleAssetsHETLIOZAdditionalInformationDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#IntangibleAssetsHETLIOZAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/IntangibleAssetsHETLIOZAdditionalInformationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/IntangibleAssetsFanaptAdditionalInformationDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#IntangibleAssetsFanaptAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/IntangibleAssetsFanaptAdditionalInformationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryofIntangibleAssetsDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#IntangibleAssetsSummaryofIntangibleAssetsDetail"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryofIntangibleAssetsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_b04f6602-107c-412c-a566-dbcce3764b42" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_71e96c1d-bc21-4f59-9c56-c8c22a55e006" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_b04f6602-107c-412c-a566-dbcce3764b42" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_71e96c1d-bc21-4f59-9c56-c8c22a55e006" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_47cf6dee-6f4c-4934-acbd-19b75b0e1238" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_b04f6602-107c-412c-a566-dbcce3764b42" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_47cf6dee-6f4c-4934-acbd-19b75b0e1238" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryofAmortizationExpenseDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#IntangibleAssetsSummaryofAmortizationExpenseDetail"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryofAmortizationExpenseDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryofFutureIntangibleAssetAmortizationDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#IntangibleAssetsSummaryofFutureIntangibleAssetAmortizationDetail"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryofFutureIntangibleAssetAmortizationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_6adb6924-c38d-408f-a38d-09912566fb45" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_41ee0114-430c-4bf3-a9df-ab92a41e928b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_6adb6924-c38d-408f-a38d-09912566fb45" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_41ee0114-430c-4bf3-a9df-ab92a41e928b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_5b775648-82ee-4860-bbcc-b0fff434e640" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_6adb6924-c38d-408f-a38d-09912566fb45" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_5b775648-82ee-4860-bbcc-b0fff434e640" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_5b9c41a8-ad01-4c5d-9fa0-db9d0b02a04b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_6adb6924-c38d-408f-a38d-09912566fb45" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_5b9c41a8-ad01-4c5d-9fa0-db9d0b02a04b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_e41d2669-da31-4f9a-a614-c83b38442838" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_6adb6924-c38d-408f-a38d-09912566fb45" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_e41d2669-da31-4f9a-a614-c83b38442838" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_ee910dee-0fe7-458a-b2ab-cd95b32fafd7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_6adb6924-c38d-408f-a38d-09912566fb45" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_ee910dee-0fe7-458a-b2ab-cd95b32fafd7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_9cd73295-e095-4384-96f2-6530436c4129" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_6adb6924-c38d-408f-a38d-09912566fb45" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_9cd73295-e095-4384-96f2-6530436c4129" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/AccountsPayableandAccruedLiabilities" xlink:type="simple" xlink:href="vnda-20201231.xsd#AccountsPayableandAccruedLiabilities"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/AccountsPayableandAccruedLiabilities" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/AccountsPayableandAccruedLiabilitiesTables" xlink:type="simple" xlink:href="vnda-20201231.xsd#AccountsPayableandAccruedLiabilitiesTables"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/AccountsPayableandAccruedLiabilitiesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/AccountsPayableandAccruedLiabilitiesDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#AccountsPayableandAccruedLiabilitiesDetail"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/AccountsPayableandAccruedLiabilitiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_713bfc90-245d-4af2-ba2f-4e84e6d0ba3a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_799405a9-f47f-45f9-9446-fcdc29ae539a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_713bfc90-245d-4af2-ba2f-4e84e6d0ba3a" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_799405a9-f47f-45f9-9446-fcdc29ae539a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_e96c6ed2-eb65-44a7-9821-f05e8dbf7328" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_713bfc90-245d-4af2-ba2f-4e84e6d0ba3a" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_e96c6ed2-eb65-44a7-9821-f05e8dbf7328" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_3590e84c-5952-452b-81bb-a3d90df1f964" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_713bfc90-245d-4af2-ba2f-4e84e6d0ba3a" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_3590e84c-5952-452b-81bb-a3d90df1f964" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_AccruedResearchAndDevelopmentExpense_78b90a7e-b56c-45e1-9a68-e20f7e3a6df6" xlink:href="vnda-20201231.xsd#vnda_AccruedResearchAndDevelopmentExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_713bfc90-245d-4af2-ba2f-4e84e6d0ba3a" xlink:to="loc_vnda_AccruedResearchAndDevelopmentExpense_78b90a7e-b56c-45e1-9a68-e20f7e3a6df6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_AccruedMilestoneObligationsUnderLicenseAgreements_6268f6e0-ecb8-48a3-ad02-97231601dd57" xlink:href="vnda-20201231.xsd#vnda_AccruedMilestoneObligationsUnderLicenseAgreements"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_713bfc90-245d-4af2-ba2f-4e84e6d0ba3a" xlink:to="loc_vnda_AccruedMilestoneObligationsUnderLicenseAgreements_6268f6e0-ecb8-48a3-ad02-97231601dd57" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_3608e49e-ab59-41af-819d-36856b57f2bf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_713bfc90-245d-4af2-ba2f-4e84e6d0ba3a" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_3608e49e-ab59-41af-819d-36856b57f2bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_df928db9-a94f-42ba-9d3e-ebf0903c57e0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_713bfc90-245d-4af2-ba2f-4e84e6d0ba3a" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_df928db9-a94f-42ba-9d3e-ebf0903c57e0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="vnda-20201231.xsd#CommitmentsandContingencies"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/CommitmentsandContingencies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesHETLIOZAdditionalInformationDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#CommitmentsandContingenciesHETLIOZAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesHETLIOZAdditionalInformationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesFanaptAdditionalInformationDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#CommitmentsandContingenciesFanaptAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesFanaptAdditionalInformationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesTradipitantAdditionalInformationDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#CommitmentsandContingenciesTradipitantAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesTradipitantAdditionalInformationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesCFTRActivatorsandInhibitorsAdditionalInformationDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#CommitmentsandContingenciesCFTRActivatorsandInhibitorsAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesCFTRActivatorsandInhibitorsAdditionalInformationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesVQW765AdditionalInformationDetails" xlink:type="simple" xlink:href="vnda-20201231.xsd#CommitmentsandContingenciesVQW765AdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesVQW765AdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesPurchaseCommitmentsDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#CommitmentsandContingenciesPurchaseCommitmentsDetail"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesPurchaseCommitmentsDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/PublicOfferingofCommonStock" xlink:type="simple" xlink:href="vnda-20201231.xsd#PublicOfferingofCommonStock"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/PublicOfferingofCommonStock" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/PublicOfferingofCommonStockDetails" xlink:type="simple" xlink:href="vnda-20201231.xsd#PublicOfferingofCommonStockDetails"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/PublicOfferingofCommonStockDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncome" xlink:type="simple" xlink:href="vnda-20201231.xsd#AccumulatedOtherComprehensiveIncome"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncome" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncomeTables" xlink:type="simple" xlink:href="vnda-20201231.xsd#AccumulatedOtherComprehensiveIncomeTables"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncomeTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncomeSummaryofAccumulatedBalancesRelatedtoEachComponentofOtherComprehensiveIncomeLossDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#AccumulatedOtherComprehensiveIncomeSummaryofAccumulatedBalancesRelatedtoEachComponentofOtherComprehensiveIncomeLossDetail"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncomeSummaryofAccumulatedBalancesRelatedtoEachComponentofOtherComprehensiveIncomeLossDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_99ae7b6d-8e4a-4b19-9d7b-f0276c607128" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_42056bec-2150-4cce-b065-ffd09103d6d2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_99ae7b6d-8e4a-4b19-9d7b-f0276c607128" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_42056bec-2150-4cce-b065-ffd09103d6d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_2feafebf-2886-446e-9d6e-ed8b28383f99" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_99ae7b6d-8e4a-4b19-9d7b-f0276c607128" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_2feafebf-2886-446e-9d6e-ed8b28383f99" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="vnda-20201231.xsd#StockBasedCompensation"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/StockBasedCompensation" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="vnda-20201231.xsd#StockBasedCompensationTables"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/StockBasedCompensationTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#StockBasedCompensationAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockOptionAdditionalInformationDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#StockBasedCompensationStockOptionAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockOptionAdditionalInformationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/StockBasedCompensationRSUAdditionalInformationDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#StockBasedCompensationRSUAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/StockBasedCompensationRSUAdditionalInformationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryofOptionActivityDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#StockBasedCompensationSummaryofOptionActivityDetail"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryofOptionActivityDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryofRSUActivityPlanDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#StockBasedCompensationSummaryofRSUActivityPlanDetail"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryofRSUActivityPlanDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/StockBasedCompensationTotalStockBasedCompensationExpenseDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#StockBasedCompensationTotalStockBasedCompensationExpenseDetail"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/StockBasedCompensationTotalStockBasedCompensationExpenseDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/StockBasedCompensationBlackScholesMertonOptionPricingModelforStockOptionsGrantedDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#StockBasedCompensationBlackScholesMertonOptionPricingModelforStockOptionsGrantedDetail"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/StockBasedCompensationBlackScholesMertonOptionPricingModelforStockOptionsGrantedDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/EmployeeBenefitPlan" xlink:type="simple" xlink:href="vnda-20201231.xsd#EmployeeBenefitPlan"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/EmployeeBenefitPlan" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/EmployeeBenefitPlanDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#EmployeeBenefitPlanDetail"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/EmployeeBenefitPlanDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/IncomeTaxes" xlink:type="simple" xlink:href="vnda-20201231.xsd#IncomeTaxes"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/IncomeTaxes" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="vnda-20201231.xsd#IncomeTaxesTables"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/IncomeTaxesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/IncomeTaxesSummaryofDomesticandForeignComponentsofIncomeBeforeIncomeTaxesDetails" xlink:type="simple" xlink:href="vnda-20201231.xsd#IncomeTaxesSummaryofDomesticandForeignComponentsofIncomeBeforeIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/IncomeTaxesSummaryofDomesticandForeignComponentsofIncomeBeforeIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_56cc973d-31b7-498e-a0c2-3083f8eb03ae" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_e4d10afd-f6f6-4c8f-a914-d31ed01ff00e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_56cc973d-31b7-498e-a0c2-3083f8eb03ae" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_e4d10afd-f6f6-4c8f-a914-d31ed01ff00e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_43cecfcc-8e3d-4c81-a057-9d8ff74cda0f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_56cc973d-31b7-498e-a0c2-3083f8eb03ae" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_43cecfcc-8e3d-4c81-a057-9d8ff74cda0f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/IncomeTaxesSummaryofProvisionBenefitforIncomeTaxesDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#IncomeTaxesSummaryofProvisionBenefitforIncomeTaxesDetail"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/IncomeTaxesSummaryofProvisionBenefitforIncomeTaxesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_4a7cbc81-802a-4a4a-b5b9-010848739613" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_a65b3f27-8c1d-4912-acad-1e5ba3577fbc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_4a7cbc81-802a-4a4a-b5b9-010848739613" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_a65b3f27-8c1d-4912-acad-1e5ba3577fbc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_268e75d8-f6c7-4d07-9393-01db8255d993" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_4a7cbc81-802a-4a4a-b5b9-010848739613" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_268e75d8-f6c7-4d07-9393-01db8255d993" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_44cc695f-ae7f-4c1b-9f37-28ece14866b6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_4a7cbc81-802a-4a4a-b5b9-010848739613" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_44cc695f-ae7f-4c1b-9f37-28ece14866b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_9a87a778-b8b2-4b8b-88ba-03beb7e8fbe5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_4a7cbc81-802a-4a4a-b5b9-010848739613" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_9a87a778-b8b2-4b8b-88ba-03beb7e8fbe5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_cc72acce-cd11-490e-93a5-caea2642010d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_4a7cbc81-802a-4a4a-b5b9-010848739613" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_cc72acce-cd11-490e-93a5-caea2642010d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_26a46b29-24a5-4c40-b7e9-5b973ee3e12f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_4a7cbc81-802a-4a4a-b5b9-010848739613" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_26a46b29-24a5-4c40-b7e9-5b973ee3e12f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/IncomeTaxesReconciliationBetweenStatutoryTaxRateandEffectiveTaxRateDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#IncomeTaxesReconciliationBetweenStatutoryTaxRateandEffectiveTaxRateDetail"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/IncomeTaxesReconciliationBetweenStatutoryTaxRateandEffectiveTaxRateDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_acf9e086-600e-4373-9ef4-72fd89233e0f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_a9a0048f-0f05-45e1-9db9-0d32436d7d88" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_acf9e086-600e-4373-9ef4-72fd89233e0f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_a9a0048f-0f05-45e1-9db9-0d32436d7d88" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_9aadf1b3-dde1-4bfb-93ae-e0ab5f8d9c16" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_acf9e086-600e-4373-9ef4-72fd89233e0f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_9aadf1b3-dde1-4bfb-93ae-e0ab5f8d9c16" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_bdd25422-4687-4d98-8e49-c116cd7dd923" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_acf9e086-600e-4373-9ef4-72fd89233e0f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_bdd25422-4687-4d98-8e49-c116cd7dd923" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_97dbc9d3-0148-423b-b9b4-d4b2e7e8f443" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_acf9e086-600e-4373-9ef4-72fd89233e0f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_97dbc9d3-0148-423b-b9b4-d4b2e7e8f443" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_EffectiveIncomeTaxRateReconciliationTaxCreditsOrphanDrug_85633926-9601-494f-bbed-278ef7e4e1f4" xlink:href="vnda-20201231.xsd#vnda_EffectiveIncomeTaxRateReconciliationTaxCreditsOrphanDrug"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_acf9e086-600e-4373-9ef4-72fd89233e0f" xlink:to="loc_vnda_EffectiveIncomeTaxRateReconciliationTaxCreditsOrphanDrug_85633926-9601-494f-bbed-278ef7e4e1f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_3a5f3bc7-ac25-47c6-9f8a-00887f2320cd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_acf9e086-600e-4373-9ef4-72fd89233e0f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_3a5f3bc7-ac25-47c6-9f8a-00887f2320cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_6b9b9f76-1154-4821-8180-401556bb105a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_acf9e086-600e-4373-9ef4-72fd89233e0f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_6b9b9f76-1154-4821-8180-401556bb105a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_EffectiveIncomeTaxRateReconciliationEffectiveTaxRateAdjustment_32a31f3a-6b6f-45c9-ac4a-0b1bdab82258" xlink:href="vnda-20201231.xsd#vnda_EffectiveIncomeTaxRateReconciliationEffectiveTaxRateAdjustment"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_acf9e086-600e-4373-9ef4-72fd89233e0f" xlink:to="loc_vnda_EffectiveIncomeTaxRateReconciliationEffectiveTaxRateAdjustment_32a31f3a-6b6f-45c9-ac4a-0b1bdab82258" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_b079c08c-8c0b-42d3-a753-69a60ba96037" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_acf9e086-600e-4373-9ef4-72fd89233e0f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_b079c08c-8c0b-42d3-a753-69a60ba96037" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_6bdae8c2-e562-410f-85c9-51aa8a5d2507" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_acf9e086-600e-4373-9ef4-72fd89233e0f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_6bdae8c2-e562-410f-85c9-51aa8a5d2507" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionsPercent_c0465bb5-075e-4c5e-8a89-7cbc528448c8" xlink:href="vnda-20201231.xsd#vnda_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionsPercent"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_acf9e086-600e-4373-9ef4-72fd89233e0f" xlink:to="loc_vnda_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionsPercent_c0465bb5-075e-4c5e-8a89-7cbc528448c8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/IncomeTaxesComponentsofNetDeferredTaxAssetsandRelatedValuationAllowanceDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#IncomeTaxesComponentsofNetDeferredTaxAssetsandRelatedValuationAllowanceDetail"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/IncomeTaxesComponentsofNetDeferredTaxAssetsandRelatedValuationAllowanceDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_48602615-0f72-4847-b546-b897c9e5d6b5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_30e8666a-3b37-4286-bd88-defd785b1d6c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_48602615-0f72-4847-b546-b897c9e5d6b5" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_30e8666a-3b37-4286-bd88-defd785b1d6c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_d6eab009-3bb1-4d5d-b681-79857c4c9f09" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_48602615-0f72-4847-b546-b897c9e5d6b5" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_d6eab009-3bb1-4d5d-b681-79857c4c9f09" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_DeferredTaxAssetsLiabilitiesBeforeValuationAllowanceNet_81d26a74-52dd-494e-8463-dafa3e2a4a7f" xlink:href="vnda-20201231.xsd#vnda_DeferredTaxAssetsLiabilitiesBeforeValuationAllowanceNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_619cfd39-f812-44ec-a1d9-d391b2d7617c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_vnda_DeferredTaxAssetsLiabilitiesBeforeValuationAllowanceNet_81d26a74-52dd-494e-8463-dafa3e2a4a7f" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_619cfd39-f812-44ec-a1d9-d391b2d7617c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_27900e8e-07e1-49da-9d94-5c20755a6386" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_vnda_DeferredTaxAssetsLiabilitiesBeforeValuationAllowanceNet_81d26a74-52dd-494e-8463-dafa3e2a4a7f" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_27900e8e-07e1-49da-9d94-5c20755a6386" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_ff7bc5de-a01b-44ba-888c-05cf7b56d2fe" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_DeferredTaxAssetsLiabilitiesBeforeValuationAllowanceNet_e2398a3d-145e-4d0d-9c9e-cfe459f7e867" xlink:href="vnda-20201231.xsd#vnda_DeferredTaxAssetsLiabilitiesBeforeValuationAllowanceNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_ff7bc5de-a01b-44ba-888c-05cf7b56d2fe" xlink:to="loc_vnda_DeferredTaxAssetsLiabilitiesBeforeValuationAllowanceNet_e2398a3d-145e-4d0d-9c9e-cfe459f7e867" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_d4ae02de-b365-4bc1-9876-5d42dd3c13ff" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_ff7bc5de-a01b-44ba-888c-05cf7b56d2fe" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_d4ae02de-b365-4bc1-9876-5d42dd3c13ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_8d244053-a19c-4cc8-83b2-f391cc252712" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_66c54dbe-2569-4140-a3e4-7df6bba4b834" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_8d244053-a19c-4cc8-83b2-f391cc252712" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_66c54dbe-2569-4140-a3e4-7df6bba4b834" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_07b7db27-53e4-4f10-9fb9-cc663cf7776b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_8d244053-a19c-4cc8-83b2-f391cc252712" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_07b7db27-53e4-4f10-9fb9-cc663cf7776b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_8338a875-352d-49cd-a743-5a54f3625850" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_8d244053-a19c-4cc8-83b2-f391cc252712" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_8338a875-352d-49cd-a743-5a54f3625850" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther_4bb0e15e-c8a9-4505-95f0-6e4aa049374b" xlink:href="vnda-20201231.xsd#vnda_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_8d244053-a19c-4cc8-83b2-f391cc252712" xlink:to="loc_vnda_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther_4bb0e15e-c8a9-4505-95f0-6e4aa049374b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_b4dba7ea-7afc-4056-a8cd-de3110d66519" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_8d244053-a19c-4cc8-83b2-f391cc252712" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_b4dba7ea-7afc-4056-a8cd-de3110d66519" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_78d198ed-d603-4e88-9d3f-1c372d135e98" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_8d244053-a19c-4cc8-83b2-f391cc252712" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_78d198ed-d603-4e88-9d3f-1c372d135e98" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/IncomeTaxesValuationAllowanceActivityonDeferredTaxAssetsDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#IncomeTaxesValuationAllowanceActivityonDeferredTaxAssetsDetail"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/IncomeTaxesValuationAllowanceActivityonDeferredTaxAssetsDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/IncomeTaxesAdditionalInformationDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#IncomeTaxesAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/IncomeTaxesAdditionalInformationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/IncomeTaxesSummaryofGrossUnrecognizedIncomeTaxBenefitsDetails" xlink:type="simple" xlink:href="vnda-20201231.xsd#IncomeTaxesSummaryofGrossUnrecognizedIncomeTaxBenefitsDetails"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/IncomeTaxesSummaryofGrossUnrecognizedIncomeTaxBenefitsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/EarningsperShare" xlink:type="simple" xlink:href="vnda-20201231.xsd#EarningsperShare"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/EarningsperShare" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/EarningsperShareTables" xlink:type="simple" xlink:href="vnda-20201231.xsd#EarningsperShareTables"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/EarningsperShareTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/EarningsperShareDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#EarningsperShareDetail"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/EarningsperShareDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_73badef0-3b9f-4e9c-af78-16c974c7f8c2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c4a40d76-89bd-43c6-a0e3-a1a1eb4bf575" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_73badef0-3b9f-4e9c-af78-16c974c7f8c2" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c4a40d76-89bd-43c6-a0e3-a1a1eb4bf575" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_9a2b193c-5fb0-4757-b230-7eddca262149" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_73badef0-3b9f-4e9c-af78-16c974c7f8c2" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_9a2b193c-5fb0-4757-b230-7eddca262149" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/LegalMatters" xlink:type="simple" xlink:href="vnda-20201231.xsd#LegalMatters"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/LegalMatters" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/QuarterlyFinancialDataUnaudited" xlink:type="simple" xlink:href="vnda-20201231.xsd#QuarterlyFinancialDataUnaudited"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/QuarterlyFinancialDataUnaudited" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/QuarterlyFinancialDataUnauditedTables" xlink:type="simple" xlink:href="vnda-20201231.xsd#QuarterlyFinancialDataUnauditedTables"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/QuarterlyFinancialDataUnauditedTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/QuarterlyFinancialDataUnauditedDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#QuarterlyFinancialDataUnauditedDetail"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/QuarterlyFinancialDataUnauditedDetail" xlink:type="extended"/>
</link:linkbase>
